scholarly journals Nivolumab plus Carboplatin and Paclitaxel as the First-line Therapy for Advanced Squamous Cell Carcinoma of the Lung with Strong Programmed Death-ligand 1 Expression: A Case Report

Cureus ◽  
2019 ◽  
Author(s):  
Frank S Fan ◽  
Chung-Fan Yang ◽  
Chia-Lin Chang
Keyword(s):  
Squamous Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Advanced Squamous Cell Carcinoma ◽  
First Line ◽  
Programmed Death Ligand 1 ◽  
First Line Therapy ◽  
Line Therapy ◽  
Programmed Death

Paclitaxel and Cisplatin as First-Line Therapy in Recurrent or Advanced Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

1999 ◽  
Vol 17 (9) ◽  
pp. 2676-2676 ◽  
Author(s):  
Peter G. Rose ◽  
John A. Blessing ◽  
David M. Gershenson ◽  
Ramon McGehee
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Gynecologic Oncology ◽  
Phase Iii ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

PURPOSE: On the basis of the activity of paclitaxel as a single agent in chemotherapy-naive squamous cell carcinoma of the cervix in a prior Gynecologic Oncology Group (GOG) trial, a phase II study of paclitaxel and cisplatin as first-line therapy was conducted by the GOG. PATIENTS AND METHODS: Eligibility included squamous cell cancer of the cervix not curable by surgery or radiation, measurable disease, WBC count ≥ 3,000/μL, platelet count ≥ 100,000/μL, serum creatinine ≥ 2 mg/100 mL, and adequate hepatic function. The starting dose was paclitaxel 135 mg/m2 infused over 24 hours followed by cisplatin 75 mg/m2 every 21 days. On the basis of toxicity, a dose escalation of paclitaxel to a maximum dose of 170 mg/m2/d was prescribed. RESULTS: Forty-seven patients were enrolled onto this study; 44 patients were assessable for toxicity and 41 for response. Forty (90.9%) had received prior radiation therapy. A median of six courses of chemotherapy was given (range, one to 10 courses). Neutropenia grade 3 (15.9%) and 4 (61.4%) was the most frequent severe adverse effect and was associated with fever in 13 patients (27.7%). Two patients (4.5%) died from neutropenic sepsis. Grade 4 thrombocytopenia occurred in 6.8% of patients. Of 41 assessable patients, five (12.2%) had complete responses and 14 (34.1%) had partial responses for an overall response rate of 46.3% (95% confidence interval, 30.7% to 62.6%). The median progression-free interval, was 5.4+ months (range, 0.3 to 22+ months) with a median survival of 10.0+ months (range, 0.9 to 22.2 months). Response was more frequent in patients with disease in nonirradiated sites (70% v 23%, P = .008). CONCLUSION: This regimen seems highly active in advanced and recurrent squamous cell carcinoma of the cervix and is currently being evaluated by the GOG in a phase III randomized study comparing the combination of paclitaxel and cisplatin with cisplatin alone.

Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: Interim results of the phase 2 CARSKIN trial.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 9534-9534 ◽  
Author(s):  
Eve Maubec ◽  
Marouane Boubaya ◽  
Peter Petrow ◽  
Nicole Basset-Seguin ◽  
Jean-Jacques Grob ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Phase 2 ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma

ORL ◽  
2020 ◽  
Vol 82 (6) ◽  
pp. 343-350
Author(s):  
Takumi Kumai ◽  
Hiroki Komatsuda ◽  
Yoshinori Minami ◽  
Yasuaki Harabuchi
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Maxillary Sinus ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

The effect of PD-1 blockade as a first-line therapy in nonmetastatic head and neck squamous cell carcinoma (HNSCC) remains unknown. We report a case of an exceptional response to PD-1 blockade as a first-line therapy in a patient with HNSCC and lung cancer. A 59-year-old man presented with cheek swelling and chest pain. He was diagnosed with maxillary sinus carcinoma (squamous cell carcinoma) and lung cancer (non-small-cell lung cancer, not otherwise specified). The maxillary sinus carcinoma was completely resolved after 8 cycles of pembrolizumab. Immune checkpoint blockade warrants further evaluation in previously untreated patients with HNSCC.

Sign in / Sign up

Export Citation Format

Share Document